Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sumana Shrestha
Institutions:
Institute of Cancer Research,
University College London
Observed institutions:
Royal Marsden NHS Foundation Trust,
University of Nottingham,
Institute of Cancer Research,
University College London
ORCID:
0000-0002-5368-0818
Observed ORCID:
0000-0002-5368-0818
OpenAlex ID:
A5062143994
Designing topographically textured microparticles for induction and modulation of osteogenesis in mesenchymal stem cell engineering
2020
·
Mahetab H. Amer
, Marta Alvarez-Paino
, et al.
·
Biomaterials
·
45
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
·
Clinical Cancer Research
·
34
PDF
Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead
2021
·
Sumana Shrestha
, Alaide Morcavallo
, et al.
·
Frontiers in Oncology
·
24
PDF
Designing Topographically Textured Microparticles for Induction and Modulation of Osteogenesis in Mesenchymal Stem Cell Engineering
2020
·
Mahetab H. Amer
, Marta Alvarez-Paino
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
4
PDF
MIF-CD74 signaling drives immune modulation in medulloblastoma
2026
·
Benjamin Draper
, Zhen You
, et al.
·
Neuro-Oncology
·
2
ID #534 Overcoming TGFβ-mediated immunosuppression to enhance B7-H3 CAR-T cell therapy in Group 3 Medulloblastoma
2026
·
Sonia Morlando
, Kamla Pillay
, et al.
·
Neuro-Oncology Pediatrics
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Data from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2023
·
Elizabeth R. Tucker
, Irene Jiménez
, et al.
Show more works
View as search
Works count:
45
Citation count:
109
H-index:
4
I10-index:
3
Year
Topic
Type